INCY Incyte
Data as of close
Industrials · Services-Commercial Physical & Biological Research
Incyte (INCY) is an industrial company in the Services-Commercial Physical & Biological Research industry, with a market capitalization of $25.1 billion. Shares last traded at $122.92, 7.3% below their 52-week high. Over the past year the stock is up 21.0%. INCY trades at a price-to-earnings ratio of 62.11, above the Services-Commercial Physical & Biological Research median of 49.44. Net profit margin is 6.7%, below the peer median of 7.4%. Revenue grew 21.2% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q3 2026 | -$3.86 | 2026-10-29 |
| Q2 2026 | $2.81 | 2026-07-28 |
| Q1 2026 | $1.47 | 2026-04-28 |
| Q4 2025 (derived) | $1.46 | 2026-02-10 |
| FY 2025 | $6.41 | 2026-02-10 |
| Q3 2025 | $2.11 | 2025-10-28 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Services-Commercial Physical & Biological Research peers
INCY vs 14 industry peers (Services-Commercial Physical & Biological Research), by market cap. Data as of close
| IQV | IQVIA | $43.5B | 31.18 | 2.51 | 8.1% | +0.45% |
| INCY | Incyte | $25.1B | 62.11 | 4.17 | 6.7% | +4.53% |
| MEDP | Medpace Holdings, Inc. | $18.4B | 35.46 | 6.47 | 18.2% | -1.08% |
| CRL | Charles River Laboratories | $15.6B | 389.09 | 3.93 | 1.0% | -7.16% |
| ABSI | Absci Corp | $1.8B | — | 1154.35 | — | +5.00% |
| OABI | OmniAb, Inc. | $755M | — | — | — | +0.39% |
| NRC | Nrc Health | $574M | 49.44 | 3.99 | 8.4% | +12.30% |
| MXCT | MAXCYTE, INC. | $142M | — | — | — | -4.83% |
| IBAC | IB Acquisition Corp. | $54M | — | — | — | -0.69% |
| ONMD | OneMedNet Corp | $27M | — | — | — | +6.03% |
| ISPC | iSpecimen Inc. | $2M | — | — | — | +7.67% |
| BIAF | bioAffinity Technologies, Inc. | $2M | — | — | — | -2.58% |
| IBACR | IB Acquisition Corp. | — | — | — | — | +1.32% |
| ICLR | Icon Plc | — | — | — | 5.4% | -0.33% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.